Spectrum Pharmaceuticals Appoints COO
News Sep 12, 2012
Mr Keller has more than twenty years experience in the pharmaceutical industry ranging from Sales and Marketing Leadership, General Management and Joint Venture Leadership in several therapeutic areas, including Oncology, Rheumatology, Dermatology and Primary Care.
"We are pleased to welcome Ken to Spectrum and believe he will be a strong asset to our management team," stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. "Ken is a leader in marketing and product launches, having directed the commercialization programs for three of Amgen's top five biologics in worldwide sales. As Spectrum prepares for increased sales of its current product portfolio and introductions of new products, we anticipate Ken's experience will be invaluable."
"I am excited to join Spectrum because the company has spectacular growth prospects. With FUSILEV, FOLOTYN and ZEVALIN, a rapidly advancing pipeline of ten drugs in development and outstanding financial strength, Spectrum is in a unique position to quickly become a leading biopharmaceutical company. The progress over the past decade has been remarkable, a solid foundation has been established and all the pieces are in place to significantly accelerate growth. I'm looking forward to helping Spectrum become the next great growth story in the biopharmaceutical industry," stated Ken Keller, Executive Vice President, Chief Operating Officer of Spectrum Pharmaceuticals, Inc.
Prior to joining Spectrum, Mr. Keller spent 21 years at Amgen. His most recent role was Vice President and General Manager, Bone Health Business Unit. Previous to this role he was responsible for the Inflammation Business Unit which contributed over $3 billion in revenue. During his career at Amgen, Mr. Keller has been the Marketing Lead or the General Manager for four of the world's top selling biologic medicines Neupogen®, Neulasta®, Aranesp® and Enbrel®. He also has significant international experience, as Managing Director for Amgen's United Kingdom and Ireland Affiliate.
Mr. Keller holds a Bachelors of Science degree in Business from Saint Johns University and a Masters in Business Administration from Loyola Marymount University.
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018